Pawsperity Biotechnologies develops advanced diagnostics and therapeutics for companion animals. They focus on leveraging biotechnology to improve animal health outcomes and extend lifespans.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for assessing animal health and disease often lack the accuracy and depth needed for early detection and personalized treatment plans. Traditional veterinary diagnostics may involve invasive procedures and fail to capture the complex molecular signatures of disease, hindering effective monitoring of therapy and diet.
Solution
Pawsperity Biotechnologies is developing advanced diagnostic tools for companion animals by leveraging molecular profiling, artificial intelligence, and machine learning. The company's technology analyzes tens of thousands of genes, proteins, metabolites, and microbes to generate high-resolution health and disease "fingerprints" for each pet. By integrating molecular data with clinical information, Pawsperity aims to provide veterinarians with actionable insights for earlier and more accurate diagnoses, reduced reliance on invasive procedures, and improved monitoring of treatment efficacy. Their approach enables a more precise and personalized approach to animal healthcare, leading to happier, healthier pets.
Target Audience
The primary target audience includes veterinarians, veterinary specialists, and animal health researchers seeking advanced diagnostic tools for companion animal healthcare.
Features
- Molecular profiling of genomics, proteomics, metabolomics, epigenetics, and cell composition from various sample types (blood, stool, tissue, urine).
- AI and machine learning algorithms to analyze complex molecular data and identify disease signatures.
- Integration of molecular data with imaging and clinical data (blood chemistry, physiologic data, pathology).
- Development of non-invasive diagnostic tests to minimize animal discomfort.
- Identification of biomarkers for early disease detection and monitoring treatment response.